Who are Trastuzumab IV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pyrotinib, Trastuzumab, Docetaxel, Trastuzumab/Hyaluronidase-oysk, Paclitaxel + Trastuzumab, epirubicin - cyclophosphamide / docetaxel + trastuzumab, [89Zr]Zr-crefmirlimab berdoxam, Venetoclax; Rituximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-iv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Trastuzumab IV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trastuzumab IV (Trastuzumab IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 3 Monoclonal antibody HER2/neu receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab IV (Trastuzumab IV) — Hoffmann-La Roche. Trastuzumab IV works by targeting and binding to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trastuzumab IV TARGET	Trastuzumab IV	Hoffmann-La Roche	phase 3	Monoclonal antibody	HER2/neu receptor
Pyrotinib, Trastuzumab, Docetaxel	Pyrotinib, Trastuzumab, Docetaxel	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Tyrosine kinase inhibitor, Monoclonal antibody, Taxane	HER2/neu receptor, HER2 protein, Microtubules
Trastuzumab/Hyaluronidase-oysk	Trastuzumab/Hyaluronidase-oysk	National Cancer Institute (NCI)	phase 3	Monoclonal antibody	HER2/neu receptor
Paclitaxel + Trastuzumab	Paclitaxel + Trastuzumab	Institut de cancérologie Strasbourg Europe	phase 3	Taxane + monoclonal antibody	Microtubules + HER2/neu receptor
epirubicin - cyclophosphamide / docetaxel + trastuzumab	epirubicin - cyclophosphamide / docetaxel + trastuzumab	GBG Forschungs GmbH	phase 3	anthracycline antibiotic/alkylating agent/taxane/monoclonal antibody	topoisomerase II/DNA/HER2/neu receptor
[89Zr]Zr-crefmirlimab berdoxam	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab IV — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-iv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing